Iterum Therapeutics (NASDAQ:ITRM) vs. Can-Fite BioPharma (NYSE:CANF) Financial Review

Iterum Therapeutics (NASDAQ:ITRM) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Institutional & Insider Ownership

9.2% of Iterum Therapeutics shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 2.0% of Iterum Therapeutics shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Iterum Therapeutics and Can-Fite BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Iterum Therapeutics	N/A	N/A	-65.54%
Can-Fite BioPharma	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Iterum Therapeutics and Can-Fite BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iterum Therapeutics	1	2	0	0	1.67
Can-Fite BioPharma	0	1	2	0	2.67

Can-Fite BioPharma has a consensus target price of $44.00, indicating a potential upside of 2,616.05%. Given Can-Fite BioPharma’s stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than Iterum Therapeutics.

Risk & Volatility

Iterum Therapeutics has a beta of 2.96, meaning that its share price is 196% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.

Valuation & Earnings

This table compares Iterum Therapeutics and Can-Fite BioPharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iterum Therapeutics	$390,000.00	4.10	-$24.77 million	($0.75)	-0.04
Can-Fite BioPharma	$405,000.00	4.28	-$7.63 million	($14.80)	-0.11

Can-Fite BioPharma has higher revenue and earnings than Iterum Therapeutics. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Can-Fite BioPharma beats Iterum Therapeutics on 8 of the 12 factors compared between the two stocks.

About Iterum Therapeutics

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.